RAPT Therapeutics (RAPT) 10-Q2024 Q1 Quarterly report

Filed: 9 May 24, 8:08am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: atopic, Canada, causation, chosen, climate, close, comment, Connecticut, CPI, CPS, disaggregated, Draft, ESG, factor, Florida, Food, gather, HNSCC, House, HPV, infer, Interagency, lift, liver, Nasdaq, ORR, path, pretreated, retrospective, retrospectively, satisfactorily, segment, SIP, stricter, Summary, transplant, unblind, undermine, wholly

Removed: accelerated, achieved, achievement, adult, allergic, amendment, amortizing, applying, attend, billion, Brazil, bundled, China, Codification, combined, constraint, cumulative, de, detected, distinct, encouraging, endpoint, exceed, exhibited, expanded, exploit, faithfully, feet, filer, Geral, harmful, Hedging, higher, iii, implementing, improvement, input, insignificant, iv, jeopardize, leased, Lei, LGPD, licensee, Macau, measuring, mg, monotherapy, multicenter, nonrefundable, occupancy, placebo, point, predominant, projected, promised, proportion, randomized, recognize, recognizing, reversal, Rule, satisfied, scheduled, showed, square, sublicense, topline, transferred, underwriting, underwritten, upfront, variable

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

RAPT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Brian Wong, Chief Executive Officer of RAPT Therapeutics, Inc. (the “Company”), and Rodney Young, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 9, 2024

In Witness Whereof, the undersigned have set their hands hereto as of the 9th day of May, 2024


/s/ Brian Wong		/s/ Rodney Young
Brian Wong		Rodney Young
President and Chief Executive Officer		Chief Financial Officer
(Principal Executive Officer)		(Principal Financial Officer and Principal Accounting Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of RAPT Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.